Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Total Current Liabilities (2016 - 2025)

RedHill Biopharma has reported Total Current Liabilities over the past 12 years, most recently at $19.2 million for Q4 2025.

  • Quarterly Total Current Liabilities fell 13.51% to $19.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.2 million through Dec 2025, down 13.51% year-over-year, with the annual reading at $19.2 million for FY2025, 13.51% down from the prior year.
  • Total Current Liabilities was $19.2 million for Q4 2025 at RedHill Biopharma, down from $22.3 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $197.5 million in Q4 2022 and troughed at $19.2 million in Q4 2025.
  • The 5-year median for Total Current Liabilities is $25.2 million (2023), against an average of $65.8 million.
  • Year-over-year, Total Current Liabilities soared 142.36% in 2022 and then crashed 89.88% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $81.5 million in 2021, then soared by 142.36% to $197.5 million in 2022, then crashed by 89.88% to $20.0 million in 2023, then grew by 11.21% to $22.2 million in 2024, then dropped by 13.51% to $19.2 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Total Current Liabilities are $19.2 million (Q4 2025), $22.3 million (Q2 2025), and $22.2 million (Q4 2024).